Invivyd, Inc. (NASDAQ:IVVD) Director Sells $34,099.20 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 75,776 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.45, for a total value of $34,099.20. Following the completion of the transaction, the director now owns 3,492,498 shares in the company, valued at $1,571,624.10. The trade was a 2.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total value of $45,261.18.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The stock was sold at an average price of $0.42, for a total value of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.51 on Friday. Invivyd, Inc. has a 1-year low of $0.40 and a 1-year high of $5.20. The business’s 50 day moving average is $0.73 and its two-hundred day moving average is $0.97. The stock has a market capitalization of $61.00 million, a P/E ratio of -0.26 and a beta of 0.53.

Hedge Funds Weigh In On Invivyd

Large investors have recently modified their holdings of the stock. Barclays PLC lifted its position in Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after buying an additional 75,780 shares during the last quarter. State Street Corp raised its stake in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Invivyd in the 3rd quarter worth about $27,000. Cubist Systematic Strategies LLC boosted its stake in shares of Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in Invivyd during the 2nd quarter valued at about $115,000. Institutional investors own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on IVVD. HC Wainwright reduced their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Invivyd in a report on Thursday, November 21st. Morgan Stanley decreased their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.